Targovax to present at Redeye's Fight Cancer conference
Targovax (OSE: TRVX), a clinical stage company developing targeted immunotherapy treatments for cancer patients, announces that members of its senior management will present at the following conference:Redeye: Fight Cancer - Immuno-oncologyDate: 20 September 2016Participants: Magnus JaderbergPresentation time: 09:40 CETVenue: Redeye AB, Stockholm, Sweden The presentation will be available to download at www.targovax.com following the event. For further information, please contact: Gunnar Gårdemyr, CEOPhone: +46 73 083 77 79Email: ggardemyr@targovax.com Øystein Soug,